mTOR and cancer: Reason for dancing at the crossroads?

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Recent successes using Gleevec for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors have provided proof that strategies to target signal transduction pathways mutated in human cancers can work. However, the application of this strategy to other cancers has been slow. Central to alleviating this impedance is the molecular characterization of the tumors. There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays.

Original languageEnglish (US)
Pages (from-to)78-84
Number of pages7
JournalCurrent Opinion in Genetics and Development
Volume16
Issue number1
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Dancing
Neoplasms
Gastrointestinal Stromal Tumors
Molecular Pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Electric Impedance
Signal Transduction

ASJC Scopus subject areas

  • Genetics

Cite this

mTOR and cancer : Reason for dancing at the crossroads? / Thomas, George.

In: Current Opinion in Genetics and Development, Vol. 16, No. 1, 02.2006, p. 78-84.

Research output: Contribution to journalArticle

@article{e013116e5c1648ad87a0783b4aa6fb88,
title = "mTOR and cancer: Reason for dancing at the crossroads?",
abstract = "Recent successes using Gleevec for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors have provided proof that strategies to target signal transduction pathways mutated in human cancers can work. However, the application of this strategy to other cancers has been slow. Central to alleviating this impedance is the molecular characterization of the tumors. There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays.",
author = "George Thomas",
year = "2006",
month = "2",
doi = "10.1016/j.gde.2005.12.003",
language = "English (US)",
volume = "16",
pages = "78--84",
journal = "Current Opinion in Genetics and Development",
issn = "0959-437X",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - mTOR and cancer

T2 - Reason for dancing at the crossroads?

AU - Thomas, George

PY - 2006/2

Y1 - 2006/2

N2 - Recent successes using Gleevec for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors have provided proof that strategies to target signal transduction pathways mutated in human cancers can work. However, the application of this strategy to other cancers has been slow. Central to alleviating this impedance is the molecular characterization of the tumors. There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays.

AB - Recent successes using Gleevec for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors have provided proof that strategies to target signal transduction pathways mutated in human cancers can work. However, the application of this strategy to other cancers has been slow. Central to alleviating this impedance is the molecular characterization of the tumors. There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays.

UR - http://www.scopus.com/inward/record.url?scp=30644468118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644468118&partnerID=8YFLogxK

U2 - 10.1016/j.gde.2005.12.003

DO - 10.1016/j.gde.2005.12.003

M3 - Article

C2 - 16359855

AN - SCOPUS:30644468118

VL - 16

SP - 78

EP - 84

JO - Current Opinion in Genetics and Development

JF - Current Opinion in Genetics and Development

SN - 0959-437X

IS - 1

ER -